Neurofilament Light Chain

This is a single-marker test measuring level of neurofilament light chain (NfL) protein in the blood or cerebrospinal fluid. Elevated levels of NfL are indicative of neuronal damage and are used as a biomarker for various neurological conditions, including multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and other neurodegenerative disorders. This test provides valuable insights into disease progression, prognosis, and response to treatment in patients with neurological diseases.

Neurofilament Light Chain (NfL), Plasma - Neurofilament light (NfL) is an intermediate filament protein found specifically in the neuronal cytoskeleton. It can be released into the extracellular space through axonal degradation, and it has been shown that varying NfL levels are an indicator of neuroaxonal damage, irrespective of the cause, and can therefore be associated with a variety of neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, or Alzheimer's disease, as well as acute situations such as traumatic brain injury and others. NfL is thus considered a promising biomarker for, disease activity, progression, prognosis, and monitoring effectiveness of therapies. As NfL can be measured in both cerebrospinal fluid (CSF) and blood, it holds great potential for routine clinical use.

This is a single-marker test measuring level of neurofilament light chain (NfL) protein in the blood or cerebrospinal fluid. Elevated levels of NfL are indicative of neuronal damage and are used as a biomarker for various neurological conditions, including multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and other neurodegenerative disorders. This test provides valuable insights into disease progression, prognosis, and response to treatment in patients with neurological diseases.